ARTICLE | Deals
Plus more antibody-drug conjugate deals: Ipsen-Sutro, Merck KGaA-Caris
By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
April 9, 2024 12:18 AM UTC
Merck is acquiring a University at Buffalo spinout for up to $208 million to improve the performance of antibody-drug conjugates in its pipeline.
An announcement by the State University of New York institution did not include the upfront payment, but said the takeout of Abceutics Inc. by Merck & Co. Inc. (NYSE:MRK) includes milestones tied to “the progress of candidates.”…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652035/deals-report-merck-buying-buffalo-academic-spinout-to-enhance-adcs